Fundraising Fox
Xalud Therapeutics, Inc.
Charlottesville, US · Delaware corporation · 5 employees on LinkedIn · 1 known investors
Find your way into Xalud Therapeutics, Inc.
25 people in our graph can introduce you to the Xalud Therapeutics, Inc. team.
Sign up to see every warm intro you have to Xalud Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Xalud Therapeutics, Inc. team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RC
Raymond ChavezVice President Research And Development2009–2025Raymond Chavez is Vice President of Research and Development at Xalud Therapeutics, where he leads gene therapy development for neurologic and joint disorders. He has over 15 years of biotech industry experience designing nonclinical programs, including FDA pre-IND submissions and IND-enabling studies, with expertise in non-viral gene therapy delivery systems and regulatory submissions.
LW
Linda WatkinsNamed on SEC filing
Board
PH
Peter HeineckeBoard director
JF
John ForsayethBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$30.5M disclosed across 3 rounds · 2015–2021
▶$18.2MraisedJun 2021 · 12 investors · BiotechnologyRule 506(b)
▶$18.2MraisedJun 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jayson RiegerDirector
- Sean StalfortDirector
- Stephen CollinsExecutive Officer, Director
- Paul B. ManningDirector
- Diem NguyenExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $18.2M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean StalfortDirector
- Stephen CollinsExecutive Officer, Director
- Jayson RiegerDirector
- Paul B. ManningDirector
- Offering amount
- $25.1M
- Amount sold
- $5M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.3MraisedJul 2015 · 1 investors · BiotechnologyRule 506(b)
▶$7.3MraisedJul 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HeineckeDirector
- Linda WatkinsDirector
- Raymond ChavezExecutive Officer, Director
- Stephen CollinsExecutive Officer, Director
- John ForsayethDirector
- Offering amount
- $7.3M
- Amount sold
- $7.3M
- Minimum investment
- $7.3M
- Proceeds to insiders
- $712.5K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Xalud Therapeutics, Inc.'s investors?
- Xalud Therapeutics, Inc.'s investors include PBM Capital.
- How much funding has Xalud Therapeutics, Inc. raised?
- Xalud Therapeutics, Inc. has disclosed $30.5M raised across 3 rounds.
- Where is Xalud Therapeutics, Inc. headquartered?
- Xalud Therapeutics, Inc. is headquartered in Charlottesville, US.